Navigation Links
TGen and Scottsdale Healthcare begin study of new drug for patients with solid tumors
Date:6/17/2014

SCOTTSDALE, Ariz. June 17, 2014 The Virginia G. Piper Cancer Center at Scottsdale Healthcare and the Translational Genomics Research Institute (TGen) are studying the safety and effectiveness of a new drug, AG-120, for treatment of patients with solid tumors, especially those with brain tumors and gallbladder bile duct cancer.

"AG-120 is designed specifically for those patients who carry the IDH1 gene mutation," said Dr. Daniel D. Von Hoff, Distinguished Professor and Physician-In-Chief at TGen, and Chief Scientific Officer for the Virginia G. Piper Cancer Center Clinical Trials at Scottsdale Healthcare, a partnership between Scottsdale Healthcare and TGen that delivers new treatments to cancer patients based on precision medicine.

The IDH1 gene mutation is most commonly found in gliomas, which make up the largest group of "primary" brain tumors, those that start in the brain. Gliomas include all tumors arising from the gluey or supportive tissue of the brain. They represent about 30 percent of all brain tumors, and about 80 percent of all malignant brain tumors.

As with all brain cancers, gliomas are difficult to treat and many grow back after surgery, radiation and standard of care chemotherapy. Many drugs cannot get to the brain because of a filtering mechanism in the body called the blood-brain barrier.

"There is a great need for more effective treatments for patients with gliomas and other solid tumors, such as gallbladder bile duct cancer," said Dr. Von Hoff, who is the Principal Investigator for AG-120 clinical trial. This study will enroll as many as 50 patients. Researchers will use precision medicine to match treatments to patient's specific genomic, or molecular, makeups.

Mutations in isocitrate dehydrogenase (IDH) 1 and 2, originally discovered in 2008, occur in the vast majority of low-grade gliomas and secondary high-grade gliomas. IDH mutations are oncogenic, meaning they have the potential to cause cancer. These mutations occur early in the formation of gliomas and in gallbladder bile duct cancer.

AG-120 is produced by Agios Pharmaceuticals Inc., based in Cambridge, Mass.

IDH1 is a metabolic enzyme identified by Agios as a protein that is mutated in a wide range of malignant tumors. Agios and its collaborators recently demonstrated that IDH1 mutations initiate and drive cancer growth by blocking differentiation, or maturation, of primitive cells. According to Agios, the inhibition of these mutated proteins may lead to clinical benefit for those cancer patients whose tumors carry them.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related medicine news :

1. TGen and Scottsdale Healthcare cancer expert Dr. Von Hoff receives Hope Funds award
2. TGen and Scottsdale Healthcare cancer expert Dr. Daniel D. Von Hoff is honored by ASCO
3. Scottsdale Treatment Center Launches Program to Address Illicit Drug Use in Adults, Adolescents
4. Home Care Assistance of Scottsdale Launches New Website
5. Luxury Arizona Condos from The Statesman Group are Now Available for Purchase in Scottsdale/Phoenix, Arizona
6. Top Phoenix Hearing Aid Provider Opens New Office in Scottsdale, AZ
7. Younan Properties Announces Successful Financing of Scottsdale Shopping Center; Retail Promenade to be Renamed 7 Thousand Shea
8. Alice Branton Invites the Eyes of the World to Focus on Scottsdale, Arizona
9. Arizona Marijuana Doctor Helps Scottsdale Patients Achieve Green Wellness in the Copper State
10. Mahendra Kumar Trivedi to Host Retreat in Scottsdale, Arizona
11. TGen-TD2-Scottsdale Healthcare breast cancer pilot study shows value of proteomic mapping
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2018)... ... December 14, 2018 , ... Becker's Hospital Review is pleased to welcome ... Bradshaw; Makeup artist and Entrepreneur Bobbi Brown; and Founder of KevinMD.com Kevin Pho, MD, ... held May 2 to 4 at the Swissotel in Chicago. The event will include ...
(Date:12/13/2018)... ... December 13, 2018 , ... Ross A. Clevens, MD, ... Hall of Fame, an honor recognizing the highest-rated and most active doctors on ... medical aesthetic providers. Dr. Clevens has been named a “Distinguished Inductee,” a distinction reserved ...
(Date:12/13/2018)... ... December 13, 2018 , ... ... M.D., to the practice’s Virginia medical team, seeing patients at SGF’s ... a full range of state-of-the-art diagnostic and treatment options for female and male ...
(Date:12/13/2018)... NEW YORK (PRWEB) , ... December 13, 2018 , ... ... combination of two classes of drugs that induces the highest rate of proliferation ever ... result is an important step toward a diabetes treatment that restores the body’s ability ...
(Date:12/13/2018)... ... December 13, 2018 , ... LifeStation today announced the availability of Find My Loved One, a ... One gives caregivers the ability to locate a loved one at any time. With ... peace of mind for children, relatives, and caregivers. , Here’s how it works: ...
Breaking Medicine News(10 mins):
(Date:12/13/2018)... REDWOOD CITY, Calif. (PRWEB) , ... December 13, ... ... company transforming infectious disease diagnostics with genomics, announced today the results of an ... The early findings showed that the Karius® Test, a non-invasive blood test that ...
(Date:12/10/2018)... ... December 10, 2018 , ... ... to announce the formation of Parkview Dental Partners (“Parkview Dental”), a dentist-founded dental ... Liszewski, founder of BayView Dental, a group dental practice comprised of 16 dentists ...
(Date:12/8/2018)... ... December 07, 2018 , ... ... management organizations in the nation, and Southwestern Eye Center, an affiliate of American ... affiliation of the two businesses will improve the quality of care for patients ...
Breaking Medicine Technology: